“`html
Belite Bio Inc. (Symbol: BLTE) shares have surpassed the average 12-month analyst target price of $93.25, trading at $93.82 on a recent date. This milestone prompts a reevaluation from analysts, who may either downgrade based on valuation or increase their price targets depending on company performance.
Analysts covering Belite Bio have diverse price targets, with one setting a low target of $80.00 and another suggesting a high of $110.00, resulting in a standard deviation of $13.5. Current ratings show 5 strong buy recommendations and 1 hold, with an average rating of 1.33, where 1 is a strong buy and 5 is a strong sell.
“`
